In addition, GITRL contributed to resistance of CLL cells to rituximab therapy, indicating that GITR/GITRL contributes to disease progression and resistance to Rituximab-induced NK reactivity in CLL [29]. Here, TNFRSF18 is linked to B-cell chronic lymphocytic leukemia.